Skip to main content
TipRanks
Go Ultimate75% OFF

Sangamo Therapeutics (0R1D) AI Stock Analysis

0 Followers
GB:0R1D

Sangamo Therapeutics

(LSE:0R1D)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Genomic medicine focusA focused genomic-medicine platform gives Sangamo exposure to therapies addressing serious diseases and preserves specialized scientific capabilities. Its research-led model can support substantial long-term value creation if investigational programs achieve clinical and regulatory success.
Negative Factors
Chapter 11 restructuringChapter 11 places the business under court-supervised restructuring and creates substantial uncertainty around asset ownership, capital allocation, and the company’s future operating structure. Delisting further reduces institutional access and signals that equity holders face an unusually weak position.

Sangamo Therapeutics (0R1D) vs. iShares MSCI United Kingdom ETF (EWC)

-100%-75%-50%-25%0%25%50%GB:0R1D-75.23%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$48.47M
Dividend Yield
―
Average Volume (3M)
55.10K
Price to Earnings (P/E)
-0.2
Beta (1Y)
0.45
Revenue Growth
-45.80%
EPS Growth
-0.16%
Country
UK
Employees
142
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Sangamo Therapeutics Business Overview & Revenue Model

Company Description

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage...

Sangamo Therapeutics Earnings Call Summary

Earnings Call Date:May 14, 2026(Q1-2026)|% Change Since:-25.69%|Next Earnings Date:Aug 11, 2026
Earnings Call SentimentNeutral

The call highlights meaningful clinical and regulatory progress for ST-920 (rolling BLA, FDA affirmation of 2-year confirmatory endpoint, durable long-term patient data) and continued advancement across neurology programs and platform technologies. However, material near-term risks center on capital availability and a NASDAQ delisting determination that forced a transition to the OTCQB market. Progress on regulatory and scientific fronts is balanced by significant financing and market-listing challenges that could impact execution and timing.

Positive Updates

BLA Rolling Submission Progress for ST-920 (Fabry)
First 2 modules of the rolling BLA for ST-920 submitted; company states the rolling submission is ~3/5 complete and anticipates completing the BLA submission as early as this summer, subject to adequate funding. FDA affirmed accelerated approval pathway using mean annualized eGFR slope at 52 weeks across all 32 dosed patients.

Negative Updates

NASDAQ Delisting Determination and Market Transition
Received a delisting determination from NASDAQ due to noncompliance with minimum bid requirements; common stock transitioned to trading on the OTCQB Venture Market under the same ticker (SGMO); company intends to appeal at a June hearing.

Company Guidance

Sangamo said the rolling BLA for ST‑920 is in progress with the first two modules submitted, the clinical module (1‑year data) already filed, management characterizing the filing as roughly 3/5 complete and anticipating BLA completion “as early as this summer” subject to securing additional funding; the FDA agreed accelerated approval can be based on mean annualized eGFR slope at 52 weeks across all 32 dosed patients, affirmed no additional confirmatory trial is required, and indicated 104‑week (2‑year) data across those 32 patients may be used for full approval (the last patient reached the 2‑year time point around April). Management also highlighted durability and safety — four patients beyond five years with supraphysiological alpha‑Gal and 17 patients off ERT (some >3 years) — and operational progress in neurology with six sites activated for the Phase I/II STAND (ST‑503), GLP toxicology for ST‑506 completed with analysis ongoing, and MHRA alignment on key matters.

Sangamo Therapeutics Risk Analysis

Sangamo Therapeutics disclosed 62 risk factors in its most recent earnings report. Sangamo Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Item 2. Unregistered sales of equity securities, use of proceeds, and issuer purchases of equity securitiesQ1, 2026
2.Item 3. Defaults upon senior securitiesQ1, 2026
3.Item 5. Other informationQ1, 2026

Sangamo Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0R1D against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CABACABA44Neutral$276.12M-0.90-106.78%――43.51%
BDTXBDTX39Underperform$84.48M-1.93-43.99%―-100.00%-302.37%
ELTXELTX39Underperform$42.46M-0.82-529.69%――46.62%
CRBUCRBU21Underperform$39.10M-0.35-102.74%―1.60%39.34%

* Healthcare Sector Average

Performance Comparison

-50%0%50%GB:0R1DCABABDTXELTXCRBUDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0R1D and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0R1DSangamo Therapeutics, Inc.0.11-0.33-75.46%
CABACabaletta Bio, Inc.1.28-1.11-46.44%
BDTXBlack Diamond Therapeutics, Inc.1.47-2.54-63.34%
ELTXElicio Therapeutics, Inc1.50-7.22-82.80%
CRBUCaribou Biosciences, Inc.0.36-1.53-80.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.